Literature DB >> 11494360

Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism.

D S Rothblat1, J A Schroeder, J S Schneider.   

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-exposed cats develop severe Parkinsonism that spontaneously resolves in 4-6 weeks. The present study examined the extent to which compensatory changes in tyrosine hydroxylase (TH) and dopamine transporter (DAT) gene and protein expression may underlie this behavioral recovery. In normal cats, TH and DAT protein levels were higher in the dorsal vs. ventral striatum. Expression of DAT and TH mRNA was higher in substantia nigra pars compacta (SNc) than in the ventral tegmental area (VTA). In symptomatic parkinsonian animals, DAT and TH protein levels were significantly decreased in all striatal areas studied. TH and DAT mRNA expression in residual SNc neurons were decreased a mean 32% and 38%, respectively. DAT gene expression in residual VTA neurons in symptomatic animals was decreased 30% whereas TH gene expression was unaffected. In spontaneously recovered cats, TH protein levels were significantly higher than the levels in symptomatic cats only in the ventral striatum, whereas no increase in DAT protein levels were observed in any striatal area. Residual neurons in most ventral mesencephalic regions of recovered cats had increased TH mRNA expression but not increased DAT gene expression, compared with symptomatic animals. Thus, increased TH protein and mRNA and suppression of DAT protein and mRNA expression in the striatum and ventral mesencephalon were associated with functional recovery from MPTP-induced parkinsonism. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494360     DOI: 10.1002/jnr.1149

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Motor cortex stimulation: mild transient benefit in a primate model of Parkinson disease.

Authors:  Alex K Wu; Kevin W McCairn; Gabriel Zada; Tiffany Wu; Robert S Turner
Journal:  J Neurosurg       Date:  2007-04       Impact factor: 5.115

Review 2.  HIV, Tat and dopamine transmission.

Authors:  Peter J Gaskill; Douglas R Miller; Joyonna Gamble-George; Hideaki Yano; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2017-04-27       Impact factor: 5.996

3.  Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons.

Authors:  Xiqun Chen; Lu Xu; Pheona Radcliffe; Baoyong Sun; A William Tank
Journal:  Mol Pharmacol       Date:  2008-03-18       Impact factor: 4.436

4.  Induction of tyrosine hydroxylase mRNA by nicotine in rat midbrain is inhibited by mifepristone.

Authors:  Pheona M Radcliffe; Carol R Sterling; A William Tank
Journal:  J Neurochem       Date:  2009-03-23       Impact factor: 5.372

5.  Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons.

Authors:  Pabla Aguirre; Natalia P Mena; Carlos M Carrasco; Yorka Muñoz; Patricio Pérez-Henríquez; Rodrigo A Morales; Bruce K Cassels; Carolina Méndez-Gálvez; Olimpo García-Beltrán; Christian González-Billault; Marco T Núñez
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

Review 6.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Authors:  Andrea Terron; Anna Bal-Price; Alicia Paini; Florianne Monnet-Tschudi; Susanne Hougaard Bennekou; Marcel Leist; Stefan Schildknecht
Journal:  Arch Toxicol       Date:  2017-12-05       Impact factor: 5.153

7.  Neuroplasticity and Neuroprotective Effect of Treadmill Training in the Chronic Mouse Model of Parkinson's Disease.

Authors:  Ewelina Palasz; Wiktor Niewiadomski; Anna Gasiorowska; Anna Mietelska-Porowska; Grazyna Niewiadomska
Journal:  Neural Plast       Date:  2019-04-03       Impact factor: 3.599

8.  miR‑335 promotes ferroptosis by targeting ferritin heavy chain 1 in in vivo and in vitro models of Parkinson's disease.

Authors:  Xinrong Li; Wenwen Si; Zhan Li; Ye Tian; Xuelei Liu; Shanyu Ye; Zifeng Huang; Yichun Ji; Caiping Zhao; Xiaoqian Hao; Dongfeng Chen; Meiling Zhu
Journal:  Int J Mol Med       Date:  2021-03-02       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.